Form 4: Verastem Director John Johnson Receives Significant Equity Compensation, Aligning Interests with Shareholders

Verastem, Inc. Director John Johnson was granted 8,333 Restricted Stock Units and 12,500 stock options, aligning his compensation with the company's performance and shareholder interests.

Summary

• John Johnson, a Director of Verastem, Inc. (VSTM), received equity compensation on May 22, 2025, as reported in a Form 4 filing.
• This compensation includes a grant of 8,333 Restricted Stock Units (RSUs) and 12,500 stock options.
• The RSUs were granted at a price of $0.00, representing a contingent right to receive one share of Common Stock per RSU.
• The stock options have an exercise price of $7.48 per share and an expiration date of May 22, 2035.
• Both the RSUs and stock options will vest in twelve equal installments.
• The first eleven installments are scheduled to vest monthly from June 2025 to April 2026.
• The final installment for both will vest on the earlier of the day before the 2026 Annual Meeting of Stockholders or May 31, 2026.
• Vesting is contingent upon Mr. Johnson's continued service as a director of Verastem, Inc.
• Following these transactions, Mr. Johnson beneficially owns 16,666 shares of Common Stock and 12,500 stock options.

Sentiment

Score: 7

Explanation: The grant of equity compensation to a director is generally a positive signal as it aligns the director's interests with shareholders and incentivizes long-term performance. It reflects a standard practice in corporate governance for retaining and motivating key personnel.

Positives

• The grant of equity compensation to a director aligns their financial interests directly with those of shareholders, incentivizing long-term company performance and value creation.
• The structured vesting schedule encourages the director's continued service and commitment to the company's strategic objectives.
• The grants are made under the Issuer's Amended and Restated 2021 Equity Incentive Plan, indicating a formal and established framework for executive and board compensation.

Risks

• The vesting of the equity compensation (RSUs and stock options) is contingent on the director's continued service, meaning the full benefits are not guaranteed if his service ceases before the vesting dates.
• The ultimate value realized from both the RSUs and stock options is directly tied to the future performance and market price of Verastem's common stock, introducing market risk.

Future Outlook

The equity grants to Director John Johnson are structured with a vesting schedule extending into 2026, contingent on his continued service, indicating an expectation of his ongoing contribution to the company's future and aligning his long-term incentives with the company's performance.

Industry Context

In the biotechnology and pharmaceutical industry, equity compensation is a prevalent practice used to attract, retain, and motivate key personnel, including directors. This grant is consistent with typical compensation structures designed to align the long-term interests of board members with the company's success in drug development, clinical trials, and potential commercialization, which are often multi-year endeavors.

Corporate Governance

Related Party Transactions

• The grant of 8,333 Restricted Stock Units and 12,500 stock options to John Johnson, a Director of Verastem, Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with those of shareholders, potentially leading to better long-term decision-making aimed at increasing shareholder value.
• Employees: While not directly impacting all employees, such grants to directors are part of a broader compensation strategy that can influence overall company culture and retention efforts by demonstrating commitment to key leadership.

Next Steps

• Continued service of John Johnson as a director of Verastem, Inc. to fulfill vesting conditions.
• Monthly vesting of RSUs and stock options from June 2025 to April 2026.
• Final vesting of RSUs and stock options on the earlier of the day before the 2026 Annual Meeting of Stockholders or May 31, 2026.

Key Dates

Keywords

Verastem, VSTM, SEC Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, Director Compensation, Corporate Governance, Biotechnology, Pharmaceuticals